Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin
Status:
Not yet recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This study intends to conduct a single-arm, prospective and open clinical study, using
carrellizumab combined with albumin-binding paclitaxel regimen for first-line treatment of
squamous cell carcinoma of the skin, including 24 patients with squamous cell carcinoma of
the skin, to further confirm the efficacy and safety of Carrellizumab combined with
albumin-binding paclitaxel in the treatment of squamous cell carcinoma of the skin.